Novo Nordisk - 42 Year Stock Split History | NVO

Stock split history for Novo Nordisk since 1982. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values.
Novo Nordisk Annual Stock Splits
Novo Nordisk Quarterly Stock Splits
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $606.535B $33.708B
Bagsv?rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $763.337B 110.33
Johnson & Johnson (JNJ) United States $363.986B 14.46
Merck (MRK) United States $331.190B 60.26
AbbVie (ABBV) United States $287.713B 14.87
AstraZeneca (AZN) United Kingdom $245.493B 21.34
Novartis AG (NVS) Switzerland $210.205B 14.90
Pfizer (PFE) United States $161.838B 20.11
Sanofi (SNY) $123.824B 11.68
Innoviva (INVA) United States $1.008B 7.08